Venkatesan Shyam has disclosed a beneficial ownership of 5.5% in ProPhase Labs, Inc., according to a recent filing. This significant stake is noteworthy as it could influence the company's direction and investor dynamics.
Background
ProPhase Labs, Inc. operates in the pharmaceutical preparations sector, specifically classified under Standard Industrial Classification 2834. The company, incorporated in Delaware, has its principal executive office located at 626 RXR Plaza, 6th Floor, Uniondale, New York. The recent filing on October 19, 2026, is a Schedule 13G, indicating Shyam's investment in the company.
What the Filing Says
The filing states that Venkatesan Shyam holds 855,101.98 shares of ProPhase Labs, representing 5.5% of the company's total shares. Shyam has sole voting and dispositive power over these shares, indicating a significant level of control.
Impact
This ownership stake may affect various stakeholders, including existing investors, management, and competitors in the pharmaceutical preparations sector. Shyam's involvement could lead to increased attention on ProPhase Labs from other investors and analysts, potentially impacting the company's market strategies.
What's Next
The filing does not say what happens next.
Ownership Details
According to the filing, Venkatesan Shyam's beneficial ownership includes 855,101.98 shares of ProPhase Labs, which accounts for approximately 5.5% of the total shares outstanding. This percentage reflects a significant investment in the company, indicating Shyam's confidence in its future prospects.
Company Information
ProPhase Labs, Inc. is classified under the Standard Industrial Classification of Pharmaceutical Preparations (SIC 2834). The company is incorporated in Delaware and has its principal executive office located at 626 RXR Plaza, 6th Floor, Uniondale, New York. The filing also notes that ProPhase Labs has a fiscal year ending on December 31.
Regulatory Compliance
The filing is submitted as a Schedule 13G, which is typically used by investors who acquire shares passively and do not intend to influence the management of the company. Shyam has certified that the shares were not acquired for the purpose of changing or influencing control of ProPhase Labs, and he is not participating in any transaction with that effect.
Contact Information
For further inquiries, Venkatesan Shyam's mailing address is listed as 7 Monet Court, Somerset, New Jersey, 08873. The filing also includes the business address for ProPhase Labs, which is 711 Stewart Ave, Suite 200, Garden City, New York, 11530.
What the Filing Does Not Include
The filing does not provide details on Shyam's future intentions regarding his stake in ProPhase Labs, nor does it mention any plans for further investment or divestment. There is also no information on the company's current financial performance or strategic initiatives that may be influenced by this ownership stake.